Drug Shortage Report for ACT LATANOPROST/TIMOLOL
Report ID | 92229 |
Drug Identification Number | 02436256 |
Brand name | ACT LATANOPROST/TIMOLOL |
Common or Proper name | LATANOPROST-TIMOLOL |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | TIMOLOL LATANOPROST |
Strength(s) | 5MG 50MCG |
Dosage form(s) | SOLUTION |
Route of administration | OPHTHALMIC |
Packaging size | 2.5ML |
ATC code | S01ED |
ATC description | ANTIGLAUCOMA PREPARATIONS AND MIOTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-08-22 |
Estimated end date | 2019-10-31 |
Actual end date | 2019-10-23 |
Shortage status | Resolved |
Updated date | 2019-10-24 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-08-22 | English | Compare |
v2 | 2019-08-22 | French | Compare |
v3 | 2019-08-23 | English | Compare |
v4 | 2019-10-03 | English | Compare |
v5 | 2019-10-03 | French | Compare |
v6 | 2019-10-24 | English | Compare |
v7 | 2019-10-24 | French | Compare |
Showing 1 to 7 of 7